Our strategy involves expanding the number of scientists who focus their research efforts on pancreatic cancer, increasing the private and public funding for their research, and encouraging them to form a cohesive network of investigators dedicated to the disease. Over the past ten years, we have awarded 80 grants to pioneering investigators and brilliant early-career scientists, totaling $12.7 million.
Increasing federal funding for pancreatic cancer research has remained a top priority as the National Cancer Institute (NCI) allocates less than 2% of its annual budget to pancreatic cancer research. While NCI’s overall budget did not increase in 2011, aggressive advocacy efforts that year drove a 2.3 percent increase in NCI funding for pancreatic cancer. We will never stop advocating for a fair share of federal funding for pancreatic cancer research.
The Pancreatic Cancer Action Network recommends that all pancreatic cancer patients consider clinical trials when exploring treatment options. The Patient and Liaison Services (PALS) program educates patients and caregivers about the value of clinical trials and conducts personalized searches in our comprehensive clinical trials database to determine potential eligibility. Clinical trials provide more options and more hope.
Events such as PurpleStride help raise valuable funds for the fight against pancreatic cancer. Equally important, the events increase awareness of the disease and the organization and educate the community about pancreatic cancer. By growing the number of event registrants every year, we move closer to achieving our 2020 goal.